⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OGEN News
Oragenics Inc.
Form 8-K
sec.gov
OGEN
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
globenewswire.com
OGEN
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
globenewswire.com
OGEN
Form 8-K
sec.gov
OGEN
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
globenewswire.com
OGEN
Form 8-K
sec.gov
OGEN
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
globenewswire.com
OGEN
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
globenewswire.com
OGEN
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
globenewswire.com
OGEN
Form 8-K
sec.gov
OGEN